These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20107914)

  • 1. Different facets of competition in the pharmaceutical sector: preliminary findings of the European Commission's sector inquiry into pharmaceuticals.
    Borkowski F
    Arch Immunol Ther Exp (Warsz); 2010 Feb; 58(1):1-5. PubMed ID: 20107914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Commission's inquiry into the pharmaceuticals sector.
    Ager B
    Lancet; 2009 Nov; 374(9704):1819; author reply 1819-20. PubMed ID: 19944861
    [No Abstract]   [Full Text] [Related]  

  • 4. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Off-patent drugs in Italy. A short-sighted view?
    Garattini L; Ghislandi S
    Eur J Health Econ; 2006 Mar; 7(1):79-83. PubMed ID: 16425040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of new drugs and indications in 2002: financial speculation or better patent care?
    Prescrire Int; 2003 Apr; 12(64):74-7. PubMed ID: 12674131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmaceutical sector inquiry: 'Hamlet' in a nutshell.
    den Exter A
    Eur J Health Law; 2010 Mar; 17(2):125-38. PubMed ID: 20443440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract]   [Full Text] [Related]  

  • 9. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
    Adamini S; Maarse H; Versluis E; Light DW
    J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. White paper. The five myths of generic competition. A Pharma Matters report. March 2009.
    Drug News Perspect; 2009 Apr; 22(3):171-5. PubMed ID: 19440560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gray marketing of pharmaceuticals.
    Chaudhry PE; Walsh MG
    J Health Care Mark; 1995; 15(3):18-22. PubMed ID: 10172516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The drug trade between European countries and developing countries].
    Bruneton C; Naboulet P; van der Heide B; Rey JL
    Med Trop (Mars); 1997; 57(4):375-9. PubMed ID: 9612781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The distribution of pharmaceuticals in Europe--current and future trends in wholesaling.
    Andersson F
    Health Policy; 1994 Mar; 27(3):271-92. PubMed ID: 10171864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Economical evaluation of drugs. A steering method for the pharmaceutical sector of the 1990's?].
    Grund J; Husbyn H
    Tidsskr Nor Laegeforen; 1994 Mar; 114(8):947-50. PubMed ID: 8191475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repercussions of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Hogan GF
    Am J Hosp Pharm; 1985 Apr; 42(4):849-51. PubMed ID: 4014238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ownership of knowledge--the role of patents in pharmaceutical R&D.
    Correa CM
    Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the impact of the Uruguay Round Agreements Act on pharmaceutical patents.
    Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Beyer A; Visaria J
    Food Drug Law J; 2009; 64(1):171-81. PubMed ID: 19998745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV
    Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.